Jaime Fergie
Pediatric Infectious Diseases · Corpus Christi, TXNPI 1679533368
Payments from drug & device makers
Across 1,119 payments — averaging $3509.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.8M
- Merck$334K
- GSK$269K
- Sanofi Pasteur Inc.$225K
- AstraZeneca$121K
- Astrazeneca UK Limited$71K
- plus $151K from 27 others
Across 6 payments — averaging $1988.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$12K
What the payments were for
- Consulting fees$230,05621%
- Speaking & faculty fees$642,83659%
- Travel & lodging$193,89118%
- Food & beverage$20,7122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 348 | $2,755,707 |
| Merck | 92 | $333,909 |
| GSK | 318 | $268,960 |
| Sanofi Pasteur Inc. | 206 | $225,399 |
| AstraZeneca(2 entities) | 9 | $121,453 |
| Astrazeneca UK Limited | 4 | $70,864 |
| Biofire Diagnostics, LLC | 17 | $34,252 |
| Modernatx, Inc. | 17 | $31,027 |
| Sanofi | 6 | $28,411 |
| Sobi, Inc | 43 | $24,681 |
| Biomerieux Inc | 13 | $21,408 |
| Novavax Inc | 9 | $5,721 |
| Argenx US, Inc. | 1 | $1,875 |
| Seqirus USA Inc | 1 | $1,158 |
| Mirum Pharmaceuticals, Inc. | 4 | $471 |
| Biogen | 5 | $382 |
| Regeneron Healthcare Solutions, Inc. | 4 | $263 |
| Travere Therapeutics, Inc. | 2 | $240 |
| Pharming Healthcare, Inc. | 2 | $224 |
| Insmed, Inc. | 2 | $127 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Rhythm Pharmaceuticals, Inc. | 1 | $112 |
| Phadia US Inc. | 2 | $104 |
| Ultragenyx Pharmaceutical Inc. | 1 | $100 |
| Novartis | 1 | $90 |
| Genentech, Inc. | 1 | $73 |
| Mylan Specialty L.p. | 2 | $33 |
| Philips North America LLC | 2 | $31 |
| Genentech USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Chiesi USA, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEXSERO$222,118
- ABRYSVO$84,236
- BEYFORTUS$76,640
- TRUMENBA$72,094
- PREVNAR 20$68,323
- PENBRAYA$62,060
- FLUZONE HIGH-DOSE$26,445
- Synagis$24,068
- Film Array System$23,936
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$17,484
- PREVNAR - 13$12,541
- ENFLONSIA$12,029
- Moderna Covid-19 Vaccine$11,600
- BIOFIRE SPOTFIRE Respiratory (R) Panel$11,502
- FLUZONE QUADRIVALENT$9,318
- FLUBLOK QUADRIVALENT$7,443
- BioFire FilmArray$5,875
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$5,564
- BIOFIRE SPOTFIRE Control Station$5,175
- MENQUADFI$4,005
How this compares
$3,927,288 in reported general payments places this provider in the 95th percentile of 66 pediatric infectious diseases providers in Texas.
Other pediatric infectious diseases in Corpus Christi
- Flor de Maria MunozHouston$9.5M
- Sheldon KaplanHouston$1.8M
- Gloria HeresiHouston$410K
- Liset Olarte CarhuazHouston$380K
- Bonnie WordHouston$330K
- Morven EdwardsHouston$301K
- Lawrence StanberryGalveston$225K
- Mary WhitworthFort Worth$134K
- Janak PatelGalveston$130K
- Norma PerezHouston$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.